Evaluation of potential biomarkers during irinotecan-based systemic treatment for colorectal cancer—study protocol of the OPTIMA study

Evaluation of potential biomarkers during irinotecan-based systemic treatment for colorectal cancer—study protocol of the OPTIMA study

Abstract Background Patients with advanced colorectal cancer (CRC) commonly receive irinotecan-based systemic treatment to alleviate symptoms, improve quality of life (QoL), and prolong overall survival (OS). However, predicting efficacy and toxicity of the treatment is challenging. Previous researc...

Full description

Saved in:
Bibliographic Details
Main Authors: E. Russ, J. Ziemons, L. E. Hillege, S. M. J. van Kuijk, E. M. de Jong, C. Elbers, M. J. Deenen, L. H. Borghuis, T. M. M. Böhm, P. Kristen, L. C. Valk, I. E. G. van Hellemond, H. Vestjens, A. Dietvorst, A. Baars, A. N. M. Goosens, L. Vermeulen, T. E. Buffart, J. de Vos-Geelen, J. Penders, M. R. Redinbo, L. Valkenburg-van Iersel, M. L. Smidt
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Cancer
Subjects:
Colorectal cancer
Irinotecan
Chemotherapy efficacy
Toxicity
Consensus molecular subtypes
UGT1A1
Online Access:https://doi.org/10.1186/s12885-025-14500-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-14500-6

Similar Items